CARM
Carisma Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−60.00%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-90.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 8, 2025 | Klichinsky Michael · officer: Chief Scientific Officer | M-Exempt | 56,982 | $0.11 |
| Oct 8, 2025 | Klichinsky Michael · officer: Chief Scientific Officer | Sale | 56,982 | $0.25 |
| Oct 3, 2025 | Klichinsky Michael · officer: Chief Scientific Officer | Sale | 165,000 | $0.26 |
| Oct 3, 2025 | Klichinsky Michael · officer: Chief Scientific Officer | Sale | 200,000 | $0.25 |
| Oct 3, 2025 | Klichinsky Michael · officer: Chief Scientific Officer | Sale | 119,347 | $0.26 |
| Jan 30, 2025 | Klichinsky Michael · officer: Chief Scientific Officer | A-Award | 221,000 | $0.50 |
| Jan 30, 2025 | Kelly Steven · director, officer: President and CEO | A-Award | 500,000 | $0.50 |
| Nov 1, 2024 | Cheng Sohanya Roshan · director | A-Award | 38,700 | $0.97 |
| Jul 1, 2024 | Thorell Marella · director | A-Award | 38,700 | $1.67 |
| Jul 1, 2024 | Scadden David · director | A-Award | 38,700 | $1.67 |
| Jun 27, 2024 | ZWEIFACH SANFORD S · director | A-Award | 19,350 | $1.22 |
| Jun 27, 2024 | Morrison Briggs · director | A-Award | 19,350 | $1.22 |
| Jun 27, 2024 | Hohneker John · director | A-Award | 19,350 | $1.22 |
| Jun 27, 2024 | Torok Michael · director | A-Award | 19,350 | $1.22 |
| Jun 18, 2024 | Morris Richard Steven · officer: Chief Financial Officer | A-Award | 85,000 | $1.03 |
| Jun 18, 2024 | Klichinsky Michael · officer: Chief Scientific Officer | A-Award | 85,000 | $1.03 |
| Jun 18, 2024 | Kelly Steven · director, officer: President and CEO | A-Award | 125,000 | $1.03 |
| Apr 1, 2024 | Hohneker John · director | A-Award | 38,700 | $2.09 |
| Feb 2, 2024 | Morris Richard Steven · officer: Chief Financial Officer | A-Award | 170,500 | $2.10 |
| Feb 2, 2024 | Klichinsky Michael · officer: Chief Scientific Officer | A-Award | 170,500 | $2.10 |
| Feb 2, 2024 | Kelly Steven · director, officer: President and CEO | A-Award | 438,000 | $2.10 |
Institutional positioning
13F filings over the trailing two quarters
New 1Increased 0Reduced 0Sold out 2
| Filer | Action | Shares | Filed |
|---|---|---|---|
| MERCK & CO., INC. | Unchanged | 1,473,240 | May 13, 2026 |
| Union Bancaire Privee, UBP SA | Unchanged | 785 | Jul 16, 2026 |
| UNION BANCAIRE PRIVEE, UBP SA | Unchanged | 785 | Apr 22, 2026 |
| GOLDEN STATE EQUITY PARTNERS | New Position | 200 | Apr 28, 2026 |
| Merck & Co., Inc. | Sold Out | 0 | May 13, 2026 |
| Ascentis Independent Advisors | Sold Out | 0 | Apr 28, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 8, 2025